

AC/SAS:gte 09/09/04  
PATENT

10/507385  
0909 Rec'd PCT/PTO 09 SEP 2004  
Express Mail Label No. EV514604138US  
Date of Deposit: September 9, 2004  
Attorney Reference Number 4239-64104-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Yoshimura

**Application No.** Not yet assigned

**Filed:** Herewith

**Confirmation No.** Not yet assigned

**For:** USE OF DISCOIDIN DOMAIN  
RECEPTOR 1 (DDR1) AND AGENTS  
THAT AFFECT THE DDR1/COLLAGEN  
PATHWAY

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 4239-64104-02

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Envelope No. EV514604138US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)



Date Mailed September 9, 2004

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Since the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicant will provide copies of such patents upon request.

LIBRARY REC'D PCT/PTO 09 SEP 2004  
10/507385

AC/SAS:gte 09/09/04  
PATENT


Express Mail Label No. EV514604138US  
Date of Deposit: September 9, 2004  
Attorney Reference Number 4239-64104-02

Applicant filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal sheet for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Anne Carlson, Ph.D.  
Registration No. 47,472

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

10/507385

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	4239-64104-02
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Yoshimura
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

## **U.S. PATENT DOCUMENTS**

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,022,694	8 Feb 2000	Radziejewski <i>et al.</i>

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	98/34954	13 Aug 1998	Vogel <i>et al.</i>

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Banchereau <i>et al.</i> , "Dendritic cells as vectors for therapy," <i>Cell</i> 106:271-274, 2001
		Bhatt <i>et al.</i> , "Discoidin domain receptor 1 functions in axon extension of cerebellar granule neurons," <i>Genes &amp; Dev.</i> 14:2216-2228, 2000
		Brand <i>et al.</i> , "Influence of extracellular matrix proteins on the development of cultured human dendritic cells," <i>Eur. J. Immunol.</i> 28:1673-1680, 1998.
		Curat <i>et al.</i> , "Mapping of epitopes in discoidin domain receptor 1 critical for collagen binding," <i>J. Biol. Chem.</i> 276:45952-45958, 2001.
		Jacob <i>et al.</i> , "Influence of non-enzymatically glycosylated collagen on monocyte-macrophage differentiation," <i>Arteriosclerosis</i> 159:333-341, 2001a
		Jacob <i>et al.</i> , "Monocyte-macrophage differentiation in three dimensional collagen lattice," <i>Biochimica et Biophysica Acta</i> 1540:50-58, 2001b
		Jönsson <i>et al.</i> , "Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells," <i>J. Cell Sci.</i> 114:2043-2053, 2001
		Kamohara <i>et al.</i> , "Discoidin domain receptor 1 isoform-a (DDR1a) promotes migration of leukocytes in three-dimensional collagen lattices," <i>FASEB J.</i> 15(14):2724-2726, 2001
		Lapteva <i>et al.</i> , "Profiling of genes expressed in human monocytes and monocyte-derived dendritic cells using cDNA expression array," <i>British Journal of Haematology</i> 114:191-197, 2001

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-64104-02
		Application Number	Not yet assigned
		Filed	10/507385 Here with
		First Named Inventor	Yoshimura
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
		L'Hôte <i>et al.</i> , "Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation," <i>FASEB J.</i> 16:234-236, 2002	
		Lu <i>et al.</i> , "Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen," <i>J. Exp. Med.</i> 179:1823-1834, 1994	
		Mahnke <i>et al.</i> , "Interaction of murine dendritic cells with collagen up-regulates allostimulatory capacity, surface expression of heat stable antigen, and release of cytokines," <i>Journal of Leukocyte Biology</i> 60:465-472, 1996	
		Matsuyama <i>et al.</i> , "Collagen-activation of discoidin domain receptor 1 isoform b (DDR1b) transduces signals that promote differentiation to macrophages and chemokine production in the human monocytic leukemia cell line, THP-1." Abstract for the 2002 Gordon conference (2002a)	
		Matsuyama <i>et al.</i> , "Discoidin domain receptor 1 (DDR1) plays a role in migration and differentiation of leukocytes in a tissue microenvironment." Abstract for 2002 AAI meeting (2002b)	
		Nemoto <i>et al.</i> , "Overexpression of protein tyrosine kinases in human esophageal cancer," <i>Pathobiology</i> 65(4):195-203, 1997 (abstract only)	
		Sakuma <i>et al.</i> , "Receptor protein tyrosine kinase <i>DDR</i> is up-regulated by p53 protein," <i>FEBS Letters</i> 398:165-169, 1996	
		Vogel <i>et al.</i> , "Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development," <i>Molecular and Cellular Biology</i> 21(8):2906-2917, April 2001	
		Vogel <i>et al.</i> , "Discoidin Domain Receptor 1 Is Activated Independently of $\beta_1$ Integrin," <i>J. Biol. Chem.</i> 275(8):5779-5784, 2000	
		Vogel, "Discoidin domain receptors: structural relations and functional implications," <i>FASEB J.</i> 13:S77-S82, 1999 Supplement	
		Vogel <i>et al.</i> , "The discoidin domain receptor tyrosine kinases are activated by collagen," <i>Molecular Cell</i> 1:13-23, December 1997	

<b>EXAMINER SIGNATURE:</b>	<b>DATE CONSIDERED:</b>
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	